Cumberland PharmaceuticalsCPIX +12.50%32 FCF Margin % is 4.03% as of Mar. 2026, which is 45% below its 10-year median of 7.37. GuruFocus rates CPIX with a GF Score™ of 32/100 and a GF Value™ of $2.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, Cumberland Pharmaceuticals ranks better than 58.98% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cumberland Pharmaceuticals (CPIX) has a FCF Margin % of 4.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cumberland Pharmaceuticals and its competitors. This is 45% below median its historical median of 7.37. According to the industry distribution chart, Cumberland Pharmaceuticals ranks #393 out of 958 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Cumberland Pharmaceuticals' FCF Margin % too high?
Cumberland Pharmaceuticals' current FCF Margin % of 4.03% is 45% below median its 10-year median of 7.37. The Drug Manufacturers industry median FCF Margin % is 2.45. Cumberland Pharmaceuticals' value of 4.03% is 64.8% above this industry median. Based on the distribution chart, Cumberland Pharmaceuticals ranks #393 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cumberland Pharmaceuticals has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cumberland Pharmaceuticals' FCF Margin % compare to CTOR and INCR?
According to the Drug Manufacturers industry distribution chart, Cumberland Pharmaceuticals ranks #393 out of 958 companies for FCF Margin %. This puts Cumberland Pharmaceuticals in the upper half of its industry. The industry median FCF Margin % is 2.45. Cumberland Pharmaceuticals' value of 4.03% is 64.8% above this benchmark. While the company's 10-year median is 7.37 vs. the industry median of 2.45, Cumberland Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cumberland Pharmaceuticals's current FCF Margin % of 4.03% is 64.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cumberland Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cumberland Pharmaceuticals's current FCF Margin % is 4.03%, which is 45% below median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cumberland Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals (CPIX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.16, compared to a current price of $6.75 — trading 212.5% above its estimated fair value. The current FCF Margin % is 4.03%, which is 45% below median its 10-year median of 7.37 and 64.8% above the Drug Manufacturers industry median of 2.45. Cumberland Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cumberland Pharmaceuticals (CPIX), the current FCF Margin % is 4.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cumberland Pharmaceuticals (CPIX) Overvalued in 2026?
Based on GuruFocus' analysis, Cumberland Pharmaceuticals stock appears to be overvalued.
The current stock price of $6.75 is trading 212.5% above its estimated GF Value™ of $2.16.
GuruFocus considers Cumberland Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CPIX:
FCF Margin %: 4.03% (45% below median its 10-year median of 7.37)
GF Value™: $2.16 vs. price of $6.75 (212.5% above fair value)
Industry Position: 64.8% above the Drug Manufacturers median (#393 of 958)
No single metric tells the full story. See the CPIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
32GF Score
Get the complete analysis for CPIX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPIX has been successfully added to your 
